Structure −Activity Relationship Studies of Targeting Ligands against Breast Cancer Cells
摘要:
A series of LXY3 (1) analogues were designed and synthesized. Their binding affinity was demonstrated using MDA-MB-231 breast cancer cells adherence inhibition assay. Further structure-activity relationship was obtained. Analogue 29 was discovered to have 3.5-fold increase of the binding affinity. Fluorescent microscopy and in vivo and ex vivo imaging studies demonstrated that 29 is tin efficient in vivo targeting agent against alpha 3 integrin of MDA-MB-231 breast tumor xenograft implant.